Uncategorized

Discover how healthcare organizations can bolster cybersecurity, enhance patient care and protect employee privacy while reducing costs through virtual mobility to access ePHI from personal devices.

EG 427 announces that it has received Investigational New Drug clearance from the U.S. Food and Drug Administration for EG110A, a gene therapy for the treatment of Neurogenic Detrusor Overactivity in Spinal Cord Injury patients.

PolTREG S.A. announces that its polyclonal Treg cell therapy PTG-007 demonstrated significant insulin secretion restoration in early-onset type-1 diabetes patients, as well as a longer period of disease remission compared to a control group receiving standard-of-care, in a long-term clinical study into the safety and efficacy of lead asset PTG-007.

SOPHiA GENETICS, a cloud-native healthcare technology company and a global leader in data-driven medicine, announced its new Residual Acute Myeloid Application.

Allecra Therapeutics and Acino announced the signing of an exclusive licensing agreement under which Acino gains the rights to commercialise Allecra’s antibiotic drug EXBLIFEP® within the Republic of South Africa and the member states of the GCC alliance, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, effective from 12 June

Takeda announced that LIVTENCITY® has been approved by the Japanese Ministry of Health, Labour and Welfare for post-transplant cytomegalovirus infection/disease that is refractory to existing anti-CMV therapies

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces the results of the Tender Offer, as set out in the Shareholder circular published by the Company on 20 May 2024.

Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that UNITY® Vitreoretinal Cataract System and UNITY® Cataract System have received U.S. Food and Drug Administration 510 clearance.

Novotech, a global full-service clinical Contract Research Organization specializing in partnering with biotech companies to expedite the development of cutting-edge therapeutics across all phases, has published a leading industry report, Liver Cancer – Global Clinical Trial Landscape.

Altimmune, Inc. presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate, in obesity, including the results of a recently completed body composition analysis, at the American Diabetes Association’s 84th Scientific Sessions.